COVID-19感染与后续甲状腺功能障碍的关联:一项国际人群倾向性评分匹配分析
该回顾性队列研究基于TriNetX国际数据库,将COVID-19患者与非COVID-19患者按倾向性评分匹配,比较12个月内甲状腺功能障碍(甲状腺毒症或甲状腺功能减退)的诊断风险。结果显示COVID-19组甲状腺功能障碍风险显著升高,短期(3个月)HR为2.07,长期(至12个月)总体HR约为2.01,且不受年龄或性别影响;作者认为需进一步研究验证。
要点
- COVID-19患者短期(3个月)甲状腺功能障碍风险升高,HR 2.07(95%CI 2.01-2.12)。
- 长期(至12个月)总体甲状腺功能障碍风险约升高2.01倍,甲状腺毒症约1.8倍,甲状腺功能减退约2.04倍。
- 年龄≥65岁者风险HR 2.18,高于<65岁者的HR 1.97;女性HR 2.12略高于男性HR 1.76。
核心结论
- COVID-19感染与12个月随访期内甲状腺功能障碍(包括甲状腺毒症和甲状腺功能减退)风险增加相关,且不受年龄或性别影响。
- 作者指出需进一步研究验证这些发现。
研究设计与样本
- 回顾性队列研究,使用TriNetX国际数据库的电子健康记录。
- 初始纳入COVID-19患者1,379,311例和非COVID-19患者6,896,814例,按年龄、性别、种族和合并症进行倾向性评分匹配。
- 主要结局为12个月内甲状腺功能障碍(甲状腺毒症或甲状腺功能减退)的诊断,采用风险比(HR)和Kaplan-Meier曲线分析,并按年龄和性别分层。
主要发现
- 短期(暴露后3个月)COVID-19组甲状腺功能障碍HR为2.07(95%CI 2.01-2.12),其中甲状腺毒症HR 2.10(95%CI 1.92-2.29),甲状腺功能减退HR 2.08(95%CI 2.01-2.13)。
- 长期(至12个月)总体甲状腺功能障碍HR约升高2.01倍,甲状腺毒症约升高1.8倍,甲状腺功能减退约升高2.04倍。
- 年龄≥65岁患者甲状腺功能障碍HR为2.18(95%CI 2.11-2.25),高于<65岁患者的HR 1.97(95%CI 1.91-2.03)。
- 女性甲状腺功能障碍HR为2.12(95%CI 2.06-2.16),男性HR为1.76(95%CI 1.69-1.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The COVID-19 pandemic's impact on thyroid function is a growing concern. Previous studies have produced inconclusive results, and there is a lack of comprehensive research into the long-term risks of thyroid dysfunction following COVID-19 infection. Methods: In this retrospective cohort study, we used data from the TriNetX international database, which includes electronic health records from a broad, diverse patient population. We compared patients with COVID-19 (cases) to those without (controls), matching for age, sex, race, and comorbidities using propensity score matching. The primary outcome was the diagnosis of thyroid dysfunction (thyrotoxicosis or hypothyroidism) within a 12-month period, analyzed using hazard ratios (HRs) and Kaplan-Meier curves, and stratified by age and sex. Results: Initially, the study included 1,379,311 COVID-19 patients and 6,896,814 non-COVID-19 patients from the TriNetX database. After matching, the cohorts were comparable in demographics and baseline characteristics. This study consistently demonstrated a significant increase in the risk of thyroid dysfunction, including thyrotoxicosis and hypothyroidism, among COVID-19 patients compared to non-COVID-19 patients. In the short term (3 months postexposure), the COVID-19 group exhibited a HR of 2.07 (95% confidence interval [CI] 2.01-2.12) for thyroid dysfunction, which included both thyrotoxicosis (HR 2.10, CI 1.92-2.29) and hypothyroidism (HR 2.08, CI 2.01-2.13). This heightened risk persisted over the long term (up to 12 months), with HRs indicating an ∼2.01-fold increased risk for overall thyroid dysfunction, a 1.8-fold increased risk for thyrotoxicosis, and a 2.04-fold increased risk for hypothyroidism. Subgroup analysis, stratified by age and sex, revealed a notably higher risk of thyroid dysfunction in patients aged 65 and above (HR 2.18, CI 2.11-2.25), compared to those in the under-65 age group (HR 1.97, CI 1.91-2.03). Both male and female patients were associated with an elevated risk, with females showing a slightly higher association with thyroid dysfunction (HR 2.12, CI 2.06-2.16) compared to males (HR 1.76, CI 1.69-1.82). Conclusions: COVID-19 infection was associated with an increased risk of thyroid dysfunction, including thyrotoxicosis and hypothyroidism, regardless of age or sex, during a 12-month follow-up period. Further research is required to validate these findings.
引用
- Huang LA, Lo SC, Yang YS, et al. Association of COVID-19 Infection with Subsequent Thyroid Dysfunction: An International Population-Based Propensity Score Matched Analysis. Thyroid. 2024. PMID: 38407979. doi:10.1089/thy.2023.0626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。